Viveve has an experienced and highly regarded Management Team, Board of Directors, and Advisory Board. Together, they provide the leadership, resources, and direction necessary to achieve commercial success.
Patricia’s commitment to the healthcare industry spans more than 25 years. Prior to joining Viveve, she served as the CEO of Prescient Medical, Inc. (PMI), a privately held company that developed diagnostic imaging catheters and coronary stents designed to reduce deaths from heart attacks. Before PMI she was the CEO of SomaLogic, a molecular diagnostic company dedicated to developing protein signature arrays. Patricia also managed several business units at Ortho-Clinical Diagnostics, a Johnson & Johnson company, and served in key executive positions at Dade Behring, a clinical diagnostics firm. In addition, she was director of cardiology systems at Cordis, a Johnson & Johnson company renowned for pioneering vascular disease treatments. There, she was responsible for launching the PALMAZ-SCHATZ® balloon-expandable stent, the first stent to achieve over a billion dollars in sales. Patricia received a B.S.E. degree in Biomedical Engineering from Duke University and completed executive business education programs at Harvard University, Massachusetts Institute of Technology, Columbia University and Northwestern University. She received the Distinguished Alumnus award from Pratt School of Engineering at Duke University in 2016.
Scott joined Viveve as Chief Financial Officer in January 2013. His 20 year career in corporate finance and strategy for the life science industry brings a wealth of finance experience to our organization. Prior to joining Viveve, he was Chief Financial Officer of Aastrom Biosciences, a publicly traded, cardiovascular cell therapy company. Before Aastrom, he spent six years as Chief Operating and Financial Officer for Prescient Medical,Inc. (PMI), a privately held company that developed diagnostic imaging catheters and coronary stents designed to reduce deaths from heart attacks. Prior to PMI, he spent several years as a financial consultant for two publicly traded biotech companies, Scios, Inc. – a Johnson & Johnson company and Alteon, Inc. He began his career in corporate finance as an investment banker in the healthcare and M&A groups at Lehman Brothers Inc., where he focused on mergers and acquisitions and financings for the life science industry. At Lehman, he successfully executed over $5 billion in transactions for medical device and biotech companies. He began his career as a Director of Neurophysiology for Biotronic, Inc. Scott received a B.S. from the University of Michigan and an M.P.H. in Health Management with Honors from the Yale University School of Medicine and School of Management.
James Atkinson has over 30 years of experience in medical device sales, marketing and business development with both Fortune 50 and start-up device companies. He joined Viveve as Chief Business Officer and President in February, 2015. Prior to joining Viveve, Mr. Atkinson was a principal at Ulthera, Inc. from October, 2006 through April, 2014, where he served as Senior Vice President of Sales and Marketing and Senior Vice President of Global Sales. While at Ulthera, he helped grow the company from 3 to 165 employees and established a global distribution network that included 42 distributors, covering 52 countries. Ulthera was purchased by Merz Aesthetics for $600 million.
Before joining Ulthera, Mr. Atkinson served as Vice President of Sales and Marketing for the Cardiac Surgery Division at St. Jude Medical, Inc. where his responsibilities included launching the Biocor® stented tissue valve, recognized as the fastest growing heart valve brand in the industry. Prior to St. Jude Medical, he served as Vice President of Sales for Medtronic Vascular, a $200 million division of Medtronic, Inc. Mr. Atkinson’s entrepreneurial spirit led him to co-found and serve as Vice President of Sales and Business Development for Medical Simulation Corporation, the leading developer of state-of-the-art simulation technologies and services for the cardiology, cardiac surgery and nursing industries. His career began as a sales representative at Ethicon Endosurgery, a Johnson and Johnson company, where he progressed through positions of increasing responsibility to Regional Manager.
Suzon Lommel has more than 30 years of experience in the medical device industry developing regulatory and quality systems. She currently serves as the Senior Vice President of Regulatory and Quality Affairs at Viveve. Prior to joining Viveve, she was Global Vice President of Regulatory and Quality Affairs at Ulthera, Inc. which was acquired by Merz Aesthetics in July, 2014. Additional prior experience includes executive and senior management roles at Breathe Technologies, Inc., Foxhollow Technologies, Inc., Advanced Stent Technology, and Boston Scientific. Suzon has extensive experience with the U.S. Food and Drug Administration and international regulatory agencies. She has authored numerous 510k, IDE, PMA, and international submissions. Ms. Lommel holds a degree in Physics from Moorpark College.
Susan joined Viveve in August of 2015 as Vice President of Global Marketing. She brings decades of experience in launching and building new categories of medical devices for novel, elective consumer-driven health and wellness brands. Susan led the marketing effort for Ulthera, the first-ever FDA-cleared procedure for non-invasive skin lifting and tightening — from inception in 2006 with 3 employees to 120 employees 6 years later and subsequent acquisition by Merz Aesthetic for $600 million. Prior to that she contributed to launching firsts in laser hair removal and laser skin resurfacing/rejuvenation (Coherent/Lumenis), radio frequency and infrared technologies for medical aesthetics (Thermage/Solta and Cutera), a time-release technology for a flagship topical pharmaceutical (Johnson & Johnson/Ortho Pharmaceuticals’ Retin-A brand), a diagnostic for detecting and monitoring osteoporosis/bone resorption (Edelman Public Relations) and the concept, innovative at the time, of in-office dispensing of pharmaceuticals and skin care (Summacare, Inc.). Her career in medical devices began as a member of the team that launched the first aesthetic medical device, an injectable for wrinkles and acne scars (Collagen Corporation/Inamed), which pioneered direct-to-consumer marketing of an FDA-cleared device. Other healthcare-related work was with Genentech (a commercialization optimization initiative) and Stanford’s Packard Children’s Hospital (Director of Community Affairs). Susan’s first job after graduating from the University of California at Berkeley was at Stanford University School of Medicine managing the research activities and publication efforts around ground-breaking advances in medical dermatology.
Debbie joined Viveve in 2015 and was promoted to Vice President of Clinical Affairs in August, 2016. She assumed additional responsibility for Medical Affairs in November, 2016. Debbie brings over 17 years of experience in life sciences including pharmaceutical, biologics, medical devices and women’s reproductive health. She has extensive clinical affairs leadership experience across multiple therapeutic areas as well as experience in operations and regulatory affairs. Debbie has launched many U.S. and international trials in women’s health, immunology, urology, orthopedics and dermatology. In connection with this work she has published numerous articles in peer-reviewed publications.
Prior to joining Viveve, Debbie served as the Director of Clinical Research for Medtronic Spine and Biologics (MDT), Medtronic’s second largest business, and managed a high profile biologic. She was Executive Director of Clinical Operations at OV Clinical Trials in Colorado and Director of Research and Development at Alita Pharmaceuticals. As an Associate Director and then Director of Clinical Operations at Duramed Research, Inc., a subsidiary of Barr Pharmaceuticals, Debbie focused on women’s health programs, including bringing Plan B emergency contraception OTC. Previous to these executive management roles, she was Director of Scientific Affairs at Women’s Capital Corporation responsible for operations, safety, FDA submissions, marketing and external collaboration, which was preceded by her role as Research Associate at The David and Lucile Packard Foundation.
Debbie received her Bachelor of Science in Chemistry degree from the University of Michigan and earned her Doctorate in Biochemistry from the Stanford University School of Medicine.
Perry joined Viveve in August 2016 as Vice President of New Technologies and was promoted to his current position in April 2017. He brings more than 25 years of experience in upstream marketing and medical product development at companies ranging from small medical device start-ups to mature, multi-national corporations. A speaker on advanced aesthetic technologies at meetings and international trade events, Perry has developed and launched products and supported market development in more than 50 countries around the world. Prior to joining Viveve, he served in various leadership and executive management roles including: Vice President of Products for Medical Aesthetics at Syneron Candela, where he was responsible for a $140M/year portfolio of laser based systems for medical aesthetics including the treatment of vascular and pigmented lesions, fractional facial resurfacing, hair removal and high-power laser tattoo removal. He served as General Manager of Marketing for ONI Medical Systems, a start-up with a premium performance MRI scanner before it was acquired by G.E. Medical Systems in 2009 and was the Director of Marketing for iCAD, Inc. a maker of women’s health – breast cancer detection systems and a Senior Product Manager at Hologic, Inc., a broad-based women’s health and imaging company.
After completing his undergraduate studies at the University of Illinois at Urbana-Champaign, Perry did Graduate Research in the Department of Surgery at the University of Illinois Medical School. He holds a Graduate Certificate in Management from the University of Massachusetts, is an AIPMM Certified Product Manager and has a number US patents, both granted and pending, for developments in the medical device space.
Jim joined Viveve as Vice President of Finance in July 2014. He brings over twenty years of accounting and finance experience in both industry and public accounting to the organization. Prior to joining Viveve, he provided accounting, finance and business consulting services for various biotech companies. From 2010 to 2012 he served as Vice President of Finance and Administration for Auxogyn, Inc., a privately held medical technology company focused on advancing women’s reproductive health by translating scientific discoveries in early embryo development into clinical solutions that improve patient outcomes in vitro fertilization (IVF) procedures. He served as Director of Finance and Vice President of Finance 2004 to 2010 for Micrus Endovascular, Inc., a company which develops, manufactures and markets both implantable and disposable medical devices used in the treatment of cerebral vascular diseases. Prior to Micrus Endovascular, Jim served at Genitope Corporation as Corporate Controller, a biotechnology company focused on the research and development of novel immunotherapies for the treatment of cancer. From 1995 to 2001, he served in management positions for high technology companies including Extricity, Inc., InVision Technologies, Inc., and Truevision, Inc. Jim was in the audit practice of Price Waterhouse, LLP from 1987 to 1995. He received his Bachelor of Business Administration with a concentration in accounting from the University of Texas at Austin and is a Certified Public Accountant.
Sean joined Viveve as Vice President of U.S. Sales in September, 2016 and brings extensive experience in medical device and aesthetic industry sales, commercial team organization, development, and management. Most recently, Sean served as Director of Sales, Merz North America, Aesthetic Device Division where he was responsible for capital and consumable sales of $100M annually directing a team of 50 regional and direct sales professionals. He led the commercial launch of the Cellfina™ System that in 12 months became the market leader generating over $15M in sales. A Regional Sales Director at Ulthera, Inc., Sean managed a team selling new ultrasound tissue lifting technology and capital equipment to physicians in the aesthetic marketplace earning top sales awards personally and with the team he led. At Zeltiq, Inc. he served as an Area Sales Manager and launched CoolSculpting®, again earning sales revenue and management awards. Prior to this, Sean had five years as a successful Area Sales Manager at Lumenis, Inc.
A known and respected sales leader in the aesthetic marketplace, Sean has consistently received annual awards and recognition for top sales dollar volume, region and territory revenue, new technology and product launches in addition to sales management and business development accomplishments.
Sean earned his Bachelor of Science in Communications from the University of Arizona.
Lori has over 20 years of leadership experience in human resources and strategic talent management in healthcare and technology industries. Prior to joining Viveve in May 2017, she was Vice President of Talent Management and Chief Administrative Officer at The Breakaway Group, a Colorado-based business that develops simulation education of HIT applications for over 1 million healthcare provider end users. Lori has held senior leadership positions demonstrating success in creating and implementing effective human capital and operational strategies in support of organizations’ mission, values and goals. She served as a human resources executive at the Association of periOperative Registered Nurses (AORN) and Evolving Systems, Inc., a software company which tripled in size prior to their IPO. Early in her career, Lori held management and sales executive positions in the cosmetics and fragrance industries with Estee Lauder and Riviera Concepts. She received her Bachelor of Arts degree in Sociology at Colorado State University and completed HR executive and business education programs at Stanford University and Vassar College.
Jim joined Viveve as Vice President of Regulatory Affairs and Quality in November 2015. He brings over 30 years of experience in the medical device industry having worked for small startups as well as large Fortune 500 companies. Prior to joining Viveve, Jim served as Senior Director of Regulatory Affairs and Quality Assurance for ViewRay, Inc., a privately held medical device company manufacturing MRI/RT systems for the treatment of cancerous tumors in the body. While at ViewRay, he achieved both ISO13485 and CE Mark certifications as well as clearances in several Asian countries. Previously, Jim served as Sr. Director RA/QA/Operations for Restoration Robotics, a privately held medical device company specializing in a vision controlled surgical robotic system used in the hair transplantation field. While at Restoration Robotics, he led efforts to gain ISO13485 and CE Mark certifications as well as multiple FDA 510(k) clearances and OUS clearances in over 30 countries within the EU, Asia, and South America.
Before joining Restoration Robotics, Mr. Talbot served in senior RA/QA positions for InSound Medical, a pioneer in developing an in-the-canal hearing aid, Boston Scientific’s Fremont CA division responsible for IVUS ultrasound systems and catheters, Cutera, a leader in the aesthetic laser industry, Cytyc Surgical, a women’s health company specializing the treatment of menorrhagia, and Acuson, a leader in diagnostic ultrasound acquired by Siemens. Jim began his career working for Hewlett-Packard’s Optoelectronic Division in Palo Alto CA as a Reliability Engineer. He received his Bachelor of Arts with a major in Physics from SUNY Potsdam and attended graduate school at Syracuse University, where he majored in Physics.
Lori Bush joined the Viveve Board in May, 2016 with over 30 years of experience in the consumer and healthcare product industries. Ms. Bush served as President and CEO of Rodan + Fields from October, 2007 to May, 2016. During her tenure, the company re-launched under a transformative social commerce model and grew to become one of the largest premium skincare brands in the U.S. Prior to joining Rodan + Fields, she served as President of Nu Skin, the global personal care division of Nu Skin Enterprises and worked at Johnson & Johnson Consumer Products Companies as the Worldwide Executive Director over Skin Care Ventures. Lori also served as the Vice President of Professional Marketing for Neutrogena.
Lori is a frequent speaker at industry and academic events, has authored numerous papers on health, beauty, and women’s leadership and is co-author of a best-selling beauty and wellness book. Her passion and career driver has been developing integrated approaches to consumer health and beauty to help women live more satisfying lives. She earned her B.S. from The Ohio State University and M.B.A. from Temple University.
Dan Janney is the Managing Partner of Alta Partners. Dan joined Alta at its founding and has over 20 years of successful early stage investing experience in life sciences. His focus on working with exceptional entrepreneurs to create companies around novel insights in biology and new approaches to drug discovery has led to the funding and development of over 35 companies. Prior to Alta, Dan was a senior investment banker at Montgomery Securities where he advised life science companies on over $8 billion of equity and merger transactions.
Dan is currently on the board of directors of several public and private companies, including Esperion Therapeutics (NASDAQ:ESPR), Evolve Biosystems, Prolacta Bioscience, Sutro Biopharma, and Viveve (NASDAQ:VIVE). In addition, he led Alta’s investments in Astex Pharmaceuticals (acquired by Supergen), Cellective (acquired by Medimmune), ChemGenex (ASX:CXS acquired by Cephalon), CoTherix (NASDAQ: CTRX acquired by Actellion), Definity Health (acquired by United Health), Dynavax (NASDAQ:DVAX), Endonetics (acquired by Medtronic), Ilex Oncology (NASDAQ:ILXO acquired by Millennium Pharmaceuticals), InterMune (NASDAQ:ITMN acquired by Roche), LJL Biosystems (NASDAQ:LJLB acquired by Molecular Devices), Mako Surgical (NASDAQ:MAKO acquired by Stryker), Neothetics (NASDAQ:NEOT), and Triangle Pharmaceuticals (NASDAQ:VIRS acquired by Gilead).
In 2006 and 2007, Dan was listed in Forbes’ Midas 100 List of Top Tech Investors. He is a member of The President’s Council of the J. David Gladstone Institutes and serves on the Board of Regents of Georgetown University. He holds a Bachelor of Arts in History from Georgetown University and a Master of Business Administration from the Anderson School at the University of California, Los Angeles.
Debora Jorn has served as a member of the Viveve board of directors since May, 2016. Ms. Jorn has 30 plus years of commercial experience building multi-billion dollar U.S. and global pharmaceutical and OTC businesses. Deb is a recognized leader in creating new markets and successfully launching products in numerous therapeutic areas. She is an expert commercial strategist who has led the consumer and physician marketing efforts for such iconic brands as Detrol LA, Ocuvite, Nasonex, Nuvaring, Jublia and Xifaxan. She also has an extensive background in several areas of Women’s Healthcare including overactive bladder, fertility, contraception, IBS-D and osteoporosis. Most recently, Deb was Executive Vice President and Group Company Chair at Valeant where she had responsibility for the Dermatology and Gastrointestinal businesses. Prior to that, she was the Chief Global Marketing Officer at Bausch & Lomb leading the prescription and OTC eye health business. Before joining Bausch & Lomb, Deb was the Group Vice President of Women’s Healthcare and Fertility at Schering Plough Corporation. She has a strong scientific background and extensive experience in all facets of the clinical development process leading to product launch including: market and competitive assessments, clinical strategy and trial design, labeling requirements for approval and competitive differentiation. PharmaVoice has recognized Ms. Jorn as “one of the top 100 most inspiring people in healthcare” in the “brand builders” category.
Arlene M. Morris joined the Viveve Board in May, 2016. Ms. Morris was previously the chief executive officer and president of Syndax Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of an epigenetic therapy for treatment-resistant cancers from April, 2012 to May, 2015 and a member of the board of directors from May, 2011 to June, 2015. Prior to Syndax, Arlene served as the president, chief executive officer and a member of the board of directors of Affymax, Inc. from 2003 to 2011, a publicly traded biotechnology company. She has held various management and executive positions at Clearview Projects, Inc., a corporate advisory firm, Coulter Pharmaceutical, Inc., a publicly traded pharmaceutical company, Scios Inc., a publicly traded biopharmaceutical company, and Johnson & Johnson, a publicly traded healthcare company. Arlene is currently a member of the board of directors of Neovacs, SA, a French publicly traded biotechnology company, Dimension Therapeutics, Biodel, Inc., and Palatin Technologies, Inc., all U.S. biopharmaceutical companies. She is also on the board of the Foundation for Research Development of the Medical University of South Carolina and previously served on the Board of BIO and the Humane Society of Silicon Valley. Ms. Morris received a B.A. in Biology from Carlow College.
Jon Plexico joins the Viveve Board of Directors with approximately 24 years of life science industry operational and advisory experience, including eight years as Managing Member and Founder of Stonepine Capital Management, LLC. Previously, Mr. Plexico was Managing Director at Merriman Curhan Ford & Co., now known as Merriman Capital, where he ran healthcare corporate finance focusing on private investments in public equity (PIPEs), secondary offerings, and mergers and acquisitions. Prior to that, Mr. Plexico was co-founding partner of Venture Ready Partners, a life science advisor providing capital raising services to private biotechnology companies. Mr. Plexico was employee #5 and served as director of business development at Chemdex Corporation, an electronic life-science commerce company that grew to 500 employees and completed an initial public offering during his tenure. He began his career at Quidel Corporation, where he became National Sales Manager for the Autoimmune Division. He has served on the Boards of Directors of Zila, Inc. and Immunetech, Inc. Mr. Plexico is a graduate of Colgate University.
Patricia’s commitment to the healthcare industry spans more than 25 years. Prior to joining Viveve, she served as the CEO of Prescient Medical, Inc. (PMI), a privately held company that developed diagnostic imaging catheters and coronary stents designed to reduce deaths from heart attacks. Before PMI she was the CEO of SomaLogic, a molecular diagnostic company dedicated to developing protein signature arrays. Patricia also managed several business units at Ortho-Clinical Diagnostics, a Johnson & Johnson company, and served in key executive positions at Dade Behring, a clinical diagnostics firm. In addition, she was director of cardiology systems at Cordis, a Johnson & Johnson company renowned for pioneering vascular disease treatments. There, she was responsible for launching the PALMAZ-SCHATZ® balloon-expandable stent, the first stent to achieve over a billion dollars in sales. Patricia received a B.S.E. degree in Biomedical Engineering from Duke University and completed executive business education programs at Harvard University, Massachusetts Institute of Technology, Columbia University and Northwestern University.
Dr. Sheryl Kingsberg is the chief of behavioral medicine at MacDonald Women’s Hospital/University Hospitals Case Medical Center and Professor in Reproductive Biology and Psychiatry at Case Western Reserve University. Her areas of clinical specialization include sexual medicine, female sexual disorders, menopause, pregnancy and postpartum mood disorders, and psychological aspects of infertility.
Dr. Kingsberg’s primary research interests are in treatments for female sexual disorders and the psychological aspects of infertility and menopause. She has been the principal investigator for several clinical trials for treatments for female sexual disorders and consults for many pharmaceutical companies that are developing investigational drug treatments for sexual problems. She has numerous publications in many national and international journals and is an Associate Editor for the Journal of Sexual Medicine and sits on the editorial board of the journal Menopause.
Dr. Kingsberg is a leader in a number of national and international organizations. She currently sits on the Board of Trustees of The North American Menopause Society, and is a past president of The International Society for the Study of Women’s Sexual Health.
Dr. Krychman is Executive Director, President, and CEO of the Southern California Center for Sexual Health and Survivorship Medicine and Associate Clinical Professor at the University of California, Irvine, Department of Obstetrics and Gynecology. He is a Member of the International Society for the Study of Women’s Sexual Health (ISSWSH), The International Society for Sexual Medicine (ISSM) and a Certified Sexual Counselor by the American Association of Sexuality Educators, Counselors and Therapists (AASECT). He served as a member of the Standards Committee for the International Society for Sexual Medicine during their 2016 International Consensus Meeting.
Dr. Krychman is an internationally recognized expert and author of numerous books addressing sexual health conditions, therapies, and treatments. He also is a primary and contributing author of many scientific clinical papers, manuscripts and presentations. Frequently asked to share his knowledge on sexual health issues, Dr. Krychman has been quoted in The Wall Street Journal, The New York Times and other media and press.
He has been a visiting professor at Oxford University in the United Kingdom and has served in a consulting or advisory board role for many women’s health companies including SHIONOGI, Boehringer Ingelheim, Pfizer Women’s Healthcare, and Viveve Medical, Inc.
Dr. Stevens is board certified by the American Board of Plastic Surgery and is a clinical professor of plastic surgery at the University of Southern California, chairman of the USC-Marina Aesthetic Surgery Fellowship and director of the USC Division of Aesthetic Surgery. He is a fellow of the American College of Surgeons and the International College of Surgeons. He was appointed by the governor to the Medical Board of California medical quality review board, and is currently co-national secretary and third vice president of the International Society of Aesthetic Plastic Surgery. Dr. Stevens also serves on the editorial board for the Aesthetic Surgery Journal. He is vice president for the American Society for Aesthetic Plastic Surgery and will become president elect in April, 2017. He earned his medical degree from Washington University School of Medicine in St. Louis, Missouri, and completed his general surgery training at Harbor-UCLA Medical Center.
Dr. Stevens also received additional training in plastic and reconstructive surgery through a competitive fellowship at Washington University-Barnes Hospital. He is the past chairman of the California Medical Association Advisory Panel on Plastic Surgery and received the Special Congressional Certificate of Recognition and the Distinguished Service Citation from the Medical Board of California.
Dr. Stevens has presented at more than 100 meetings and delivered over 300 invited talks both nationally and internationally. Additionally, he has authored more than 70 articles and chapters on aesthetic plastic surgery.